Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2–induced systemic toxicity

Extrapulmonary manifestations of COVID-19 are associated with a much higher mortality rate than pulmonary manifestations. However, little is known about the pathogenesis of systemic complications of COVID-19. Here, we create a murine model of SARS-CoV-2–induced severe systemic toxicity and multiorgan involvement by expressing the human ACE2 transgene in multiple tissues via viral delivery, followed by systemic administration of SARS-CoV-2. The animals develop a profound phenotype within 7 days with severe weight loss, morbidity, and failure to thrive. We demonstrate that there is metabolic suppression of oxidative phosphorylation and the tricarboxylic acid (TCA) cycle in multiple organs with neutrophilia, lymphopenia, and splenic atrophy, mirroring human COVID-19 phenotypes. Animals had a significantly lower heart rate, and electron microscopy demonstrated myofibrillar disarray and myocardial edema, a common pathogenic cardiac phenotype in human COVID-19. We performed metabolomic profiling of peripheral blood and identified a panel of TCA cycle metabolites that served as biomarkers of depressed oxidative phosphorylation. Finally, we observed that SARS-CoV-2 induces epigenetic changes of DNA methylation, which affects expression of immune response genes and could, in part, contribute to COVID-19 pathogenesis. Our model suggests that SARS-CoV-2–induced metabolic reprogramming and epigenetic changes in internal organs could contribute to systemic toxicity and lethality in COVID-19.

[1]  P. Enríquez,et al.  Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19 , 2020, Critical Care.

[2]  P. Pickkers,et al.  Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. , 2020, JAMA.

[3]  M. Mori,et al.  Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis , 2020, Cell Metabolism.

[4]  Y. Umemura,et al.  Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy , 2020, Journal of clinical medicine.

[5]  Daniel J. Gould,et al.  Cutaneous Manifestations of COVID-19: An Evidence-Based Review , 2020, American Journal of Clinical Dermatology.

[6]  Lisa E. Gralinski,et al.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.

[7]  H. Kamel,et al.  Effects of COVID-19 on the Nervous System , 2020, Cell.

[8]  Lior Pachter,et al.  Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing , 2020, medRxiv.

[9]  S. Moolamalla,et al.  Host metabolic reprogramming in response to SARS-Cov-2 infection , 2020, bioRxiv.

[10]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[11]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[12]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[13]  A. B. Reddy,et al.  COVID-19 management in light of the circadian clock , 2020, Nature Reviews Molecular Cell Biology.

[14]  Dain R. Brademan,et al.  Large-Scale Multi-omic Analysis of COVID-19 Severity , 2020, Cell Systems.

[15]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[16]  Chengliang Zhu,et al.  Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19 , 2020, Frontiers in Molecular Biosciences.

[17]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[18]  R. Muniyappa,et al.  Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course , 2020, Endocrinology.

[19]  Huanhuan Gao,et al.  Proteomic and Metabolomic Characterization of COVID-19 Patient Sera , 2020, Cell.

[20]  G. Fonarow,et al.  Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. , 2020, JAMA cardiology.

[21]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[22]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[23]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[24]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[25]  N. Chandel,et al.  Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.

[26]  R. Terkeltaub,et al.  Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production. , 2019, Cell metabolism.

[27]  Robyn M. Kaake,et al.  Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication , 2018, Cell.

[28]  Robert H. Bell,et al.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. , 2015, Cell reports.

[29]  Hong Wang,et al.  Hyperhomocysteinemia and Endothelial Dysfunction. , 2009, Current hypertension reviews.

[30]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[32]  T. Kohda,et al.  A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. , 2001, Genomics.

[33]  R. Hammer,et al.  Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. , 1998, Development.

[34]  T. Bourgeron,et al.  Clinical presentation of mitochondrial disorders in childhood , 1996, Journal of Inherited Metabolic Disease.

[35]  K. Tanzawa,et al.  Cloning and functional expression of human endothelin-converting enzyme cDNA. , 1995, Biochemical and biophysical research communications.

[36]  Kenji Nakamura,et al.  Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality , 2006, Nature Genetics.